Use this URL to cite or link to this record in EThOS:
Title: Structural studies of neuropilin-1
Author: Yelland, T. S.
ISNI:       0000 0004 7229 5768
Awarding Body: UCL (University College London)
Current Institution: University College London (University of London)
Date of Award: 2015
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Restricted access.
Access from Institution:
Neuropilin-1 (Nrp1) is ~130kDa multidomain type I transmembrane protein with no intrinsic enzymatic activity. Instead, acting as co-receptor in conjunction with other membrane proteins such as vascular endothelial growth factor receptors VEGFRs and plexins, neuropilins regulate key processes in vasculogenesis and neuronal cell development. The functional flexibility of neuropilins can be attributed to their multidomain composition. NRPs contain five extracellular domains: two CUB domains (homologous to complement binding factors) labelled a1 and a2; two coagulation factor domains, labelled b1 and b2, with homology to C1/C2 domains of factor FV/VIII; and a membrane-proximal MAM (meprin/antigen 5/ receptor tyrosine phosphotase μ) domain, labelled c. The cytoplasmic portion of a neuropilin molecule, comprises a small 44 residue-long domain that is structurally uncharacterized. Most research efforts have focused on the extracellular ligand binding a1a2b1b2 domains. This thesis will describe my PhD work which has focused on structural determination of the two poorly characterized domains of human neuropilin-1: MAM (c) domain - believed to be required for neuropilin dimerization, and the short cytoplasmic domain which is linked to VEGF signalling, NRP1 recycling, association with PDZ domain-containing intracellular proteins, and blood vessels permeability. This work utilised a variety of complimentary techniques including x-ray crystallography, NMR, ITC and CD shedding light on how these domains carry out their biological function. Furthermore, the potential medical significance of Nrp1 means that it is a valid anti-cancer therapeutic target. A number of co-crystallised structures are presented of the b1 domain in complex with small ligands in an on-going drug development collaboration with an industry partner.
Supervisor: Djordjevic, S. ; Driscoll, P. Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID:  DOI: Not available